Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Entire DC Network
Reducing Return Of Disease Activity In Patients With Relapsing Multiple Sclerosis Transitioned From Natalizumab To Teriflunomide: 12-Month Interim Results Of Teriflunomide Therapy., Stanley Cohan, Keith Edwards, Lindsay Lucas, Tiffany Gervasi-Follmar, Judy O'Connor, Jessica Siuta, Vineetha Kamath, Lore Garten, Chiayi Chen, James Thomas, Kyle E Smoot, Kiren Kresa-Reahl, Kateri Spinelli
Reducing Return Of Disease Activity In Patients With Relapsing Multiple Sclerosis Transitioned From Natalizumab To Teriflunomide: 12-Month Interim Results Of Teriflunomide Therapy., Stanley Cohan, Keith Edwards, Lindsay Lucas, Tiffany Gervasi-Follmar, Judy O'Connor, Jessica Siuta, Vineetha Kamath, Lore Garten, Chiayi Chen, James Thomas, Kyle E Smoot, Kiren Kresa-Reahl, Kateri Spinelli
Articles, Abstracts, and Reports
Background: Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need for follow-up therapeutic strategies.
Objective: To assess the efficacy of teriflunomide following natalizumab discontinuance in relapsing multiple sclerosis patients.
Methods: Clinically stable relapsing multiple sclerosis patients completing 12 or more consecutive months of natalizumab, testing positive for anti-John Cunningham virus antibody, started teriflunomide 14 mg/day, 28 ± 7 days after their final natalizumab infusion. Physical examination, Expanded Disability Status Scale, laboratory assessments, and brain magnetic resonance imaging were performed at screening and multiple follow-up visits.
Results: Fifty-five patients were enrolled …